Abstract
Summary
KEY FINDINGS
The North America nasal spray market is set to project a CAGR of 9.23% during the forecast period, 2021-2028. The surging respiratory diseases have raised the demand for nasal spray in North America. Also, the US is one of the biggest markets for nasal sprays. The region benefits from the presence of well-established companies like Allergan Inc and Pfizer Inc. Moreover, Canada and the United States have an increasing elderly population, vulnerable to respiratory diseases. Further, the rising allergic disorders and high acceptance of self-administration of medication increase the market demands.
MARKET INSIGHTS
The United States and Canada are evaluated for the North America nasal spray market growth analysis. In Canada, allergic rhinitis (AR) affects 1 in 5 people, with 80% of asthma patients also suffering from sinusitis or allergic rhinitis, as per industry sources. In addition, AR is a common disorder linked to conjunctivitis and asthma. Further, chronic rhinosinusitis (CRS) is an inflammatory disease with a 5% prevalence in Canada. Moreover, over 3 million Canadians have 1 of 5 serious respiratory diseases like COPD (chronic obstructive pulmonary disease), cystic fibrosis, tuberculosis (TB), and lung cancer. Therefore, the considerable increase in respiratory allergies and diseases propel the market growth.
Furthermore, in countries like the United States, with the rising aging population, lung diseases like COPD and idiopathic pulmonary fibrosis (IPF) are growing. Also, air pollution is increasing the risk of several respiratory diseases like COPD.
COMPETITIVE INSIGHTS
Some of the major firms in the market include Pfizer Inc, Proctor & Gamble Co (P&G), Johnson & Johnson, SaNotize Research and Development, Novartis International AG, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
1 RESEARCH SCOPE & METHODOLOGY
1.1 STUDY OBJECTIVES
1.2 SCOPE OF STUDY
1.3 METHODOLOGY
1.4 ASSUMPTIONS & LIMITATIONS
2 EXECUTIVE SUMMARY
2.1 MARKET SIZE & ESTIMATES
2.2 MARKET OVERVIEW
3 MARKET DYNAMICS
3.1 KEY DRIVERS
3.1.1 RISING ADOPTION OF NASAL SPRAYS AMONG PATIENTS
3.1.2 GROWING ACCEPTANCE OF SELF-MEDICATION
3.1.3 INCREASING INTRANASAL VACCINES FOR COVID-19
3.2 KEY RESTRAINTS
3.2.1 OVERUSE RISKS ASSOCIATED WITH NASAL SPRAYS
4 KEY ANALYTICS
4.1 IMPACT OF COVID-19 ON NASAL SPRAY MARKET
4.2 KEY MARKET TRENDS
4.3 PORTER’S FIVE FORCES ANALYSIS
4.3.1 BUYERS POWER
4.3.2 SUPPLIERS POWER
4.3.3 SUBSTITUTION
4.3.4 NEW ENTRANTS
4.3.5 INDUSTRY RIVALRY
4.4 OPPORTUNITY MATRIX
4.5 VENDOR LANDSCAPE
5 MARKET BY PRODUCT
5.1 DECONGESTION NASAL SPRAY
5.2 STEROID NASAL SPRAY
5.3 SALTWATER SOLUTION/SALINE NASAL SPRAY
6 MARKET BY PRESCRIPTION
6.1 OVER THE COUNTER
6.2 PRESCRIBED
7 MARKET BY THERAPEUTIC
7.1 ANTIHISTAMINE
7.2 NASAL STEROIDS
7.3 ANTICHOLINERGIC
7.4 MAST CELL INHIBITOR
8 MARKET BY APPLICATION
8.1 NASAL CONGESTION
8.2 ALLERGIC AND NON-ALLERGIC RHINITIS
8.3 VACCINATION
8.4 CNS DISORDERS
8.5 OTHER APPLICATIONS
9 MARKET BY END-USER
9.1 HOME CARE SETTING
9.2 ASC/CLINICS
9.3 PHARMACY
9.4 HOSPITAL
9.5 OTHER END-USERS
10 GEOGRAPHICAL ANALYSIS
10.1 NORTH AMERICA
10.1.1 MARKET SIZE & ESTIMATES
10.1.2 KEY DRIVERS
10.1.3 KEY CHALLENGES
10.1.4 KEY PLAYERS
10.1.5 COUNTRY ANALYSIS
- 10.1.5.1 UNITED STATES
- 10.1.5.2 CANADA
11 COMPETITIVE LANDSCAPE
11.1 KEY STRATEGIC DEVELOPMENTS
11.1.1 MERGERS & ACQUISITIONS
11.1.2 PARTNERSHIPS & AGREEMENTS
11.2 COMPANY PROFILES
11.2.1 AKORN INCORPORATED
11.2.2 ALLERGAN PLC
11.2.3 APOTEX INC
11.2.4 BHARAT BIOTECH
11.2.5 CATALENT INC
11.2.6 CIPLA LIMITED
11.2.7 GLAXOSMITHKLINE PLC
11.2.8 JOHNSON & JOHNSON
11.2.9 NOVARTIS INTERNATIONAL AG
11.2.10 PFIZER INC
11.2.11 PROCTOR & GAMBLE CO (P&G)
11.2.12 SANOTIZE RESEARCH AND DEVELOPMENT
11.2.13 SUN PHARMACEUTICALS INDUSTRIES LTD
11.2.14 TEVA PHARMACEUTICALS INDUSTRIES LTD
11.2.15 VIATRIS